Organon & CoChange company Symbol lookupSelect an option...OGN Organon & CoCPSI Computer Programs and Systems IncTKNO Alpha Teknova IncBTM Bitcoin Depot IncRC Ready Capital CorpNEOV NeoVolta IncSCHL Scholastic CorpSIDU Sidus Space IncMGY Magnolia Oil & Gas CorpCWBR CohBar IncGo
Change company Symbol lookup
Select an option...
OGN Organon & Co
CPSI Computer Programs and Systems Inc
TKNO Alpha Teknova Inc
BTM Bitcoin Depot Inc
RC Ready Capital Corp
NEOV NeoVolta Inc
SCHL Scholastic Corp
SIDU Sidus Space Inc
MGY Magnolia Oil & Gas Corp
CWBR CohBar Inc
Health Care : Pharmaceuticals | Small Cap Value
Company profileOrganon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (Organon Products). Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing, Follistim AQ, and Elonva. The Company’s Biosimilars portfolio spans immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates its manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 8, 2023 | $1.31 | Q2 Consensus of 6 analysts | $1.01 | Difference from consensus | 30.09% | Q3 Earnings will announce | (Unconfirmed) November 1, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
OGN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.